Skip to main content

Published locations for Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib

User login

  • Reset your password
  • /content/alectinib-provides-new-option-alk-positive-nsclc-patients-after-progression-crizotinib
  • /jcso/article/110035/lung-cancer/alectinib-provides-new-option-alk-positive-nsclc-patients-after
  • /thoracicsurgerynews/article/110035/lung-cancer/alectinib-provides-new-option-alk-positive-nsclc
  • /hematology-oncology/article/110035/lung-cancer/alectinib-provides-new-option-alk-positive-nsclc